High Purity Anastrozole

• Post Date:

  Jan 05,2017

• Expiry Date:

  Jan 05,2018

• Detailed Description:

  High Purity Anastrozole
  
  99% Purity of Anastrozole / CAS No: 120511-73-1
  
  Product details:
  Product name: Anastrozole
  Synonym: ARIMIDEX
  CAS No: 120511-73-1
  Molecular Formula: C17H19N5
  Molecular Weight: 293.37
  Assay: 99%
  Packing: 1kg/aluminum foil bag
  Appearance: White to white crystalline powder
  Usage: An aromatase inhibitor. Used as an antineoplastic raw materials.
  Storage: shading, confined preservation
  
  Product description:
  Anastrozole (INN) (marketed under the trade name Arimidex by AstraZeneca) is a non-steroidal aromatase-inhibiting drug approved for treatment ofbreast cancer after surgery, as well as for metastasis in both pre and post-menopausal women. The severity of breast cancer can be increased byestrogen, as sex hormones cause hyperplasia, and differentiation at estrogen receptor sites. Anastrozole works by inhibiting the synthesis of estrogen. The patent on Arimidex by AstraZeneca expired June 2010.
  
  Medical uses
  
  The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial was an international randomised controlled trial of 9366 women with localized breast cancer who received either anastrozole, tamoxifen, or both for five years, followed by five years of follow-up. After more than 5 years the group that received anastrozole had significantly better clinical results than the tamoxifen group. The trial suggested that anastrozole is the preferred medical therapy for postmenopausal women with localized breast cancer, which is estrogen receptor (ER) positive. Another study found that the risk of recurrence was reduced 40%, but was associated with an increased risk of bone fractures. The study concluded that ER positive patients benefited from switching from tamoxifen to anastrozole in patients who have completed 2 years' adjuvant tamoxifen. A more recent trial found that anastrozole significantly reduced the incidence of breast cancer in postmenopausal women relative to placebo, and while there were side effects related to estrogen deprivation observed, the researchers concluded that this was probably not related to the treatment. Lead author Jack Cuzick was quoted by the BBC as saying, "This class of drugs is more effective than previous drugs such as tamoxifen and crucially, it has fewer side effects," adding that he thought there was now enough evidence to support offering the drug.
  
  E-mail:alice@ycgmp.com
  

• Company:

  Wuhan Yuancheng Gongchuang Technology Co.,Ltd     [ China ]        

• Contact:

  alice111

• Tel:

  +86-027-50756242

• Fax:

  86-27-88048077

• Email:

  alice@ycgmp.com